eus-gallbladder vs cds as first line in mbdo- palliative (carpegiem trial)

Conditions: Malignant Biliary Obstruction; Biliary Tract Neoplasms; Pancreatic Cancer Non-resectable

Summary: the aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (lams) with a coaxial double-pigtail plastic stent (dps) in eus-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients.

ecoendoscopy-guided choledochoduodenostomy (eus-cds) with a biliary lumen-apposing metal stent (lams) has been widely accepted as a second line treatment in cases of ercp failure in malignant distal biliary obstruction (mdbo). recent studies (drambo and element trial) compared eus-cds vs ercp as a first line treatment in mdbo in palliative patients, showing similar clinical and techinal success and adverse events rate between both techniques, demonstrating that both procedures could be options for primary biliary drainage in unresectable mdbo. furthermore a recent clinical trial (bampi trial) has proven that the addition of a coaxial double pigtail (dps) offers benefits in terms of safey and clinical success. in the last years there has been an increasing interest for the eus-guided gallblader drainage (eus-gbd) in unresectable mdbo as an alternative for eus-cds, and recent studies and reviews have been reported with acceptable techinal and clinical success, but no clinical trial has been performed up to date. our hypothesis is that eus-gbd may offer benefits in terms of safety over eus-cds, maintaining similar clinical and techinal success rates.

Eligibility criteria:
inclusion criteria: * malignant distal biliary obstruction diagnosed in patient considered paliative with biliary drainage indication. * consensual malignancy by a bilio-pancreatic multidisciplinar committe (histological confirmation is not mandatory) * patient capable of understanding and/or singning the informed consent. * patient who understands the type of study and will comply with all follow-up tests throughout its duration exclusion criteria: * pregnancy or lactation. * severe coagulation disorder: inr \> 1.5 non correctable with plasma administration and/or platelet count \< 50.000/mm3. * previous cholecistectomy or gallblader perforation. * tumoral obstruction of cystic duct. * multiple liver metastases affecting more than 30% of the liver parenchyma * distal malignant biliary strictures in patients considered resectable or borderline. * benign or uncertain etiology of biliary strictures or strictures located proximally or in close proximity to the hilum. * patients with prior biliary stents or other biliary drainages (e.g., ptcd). * altered intestinal anatomy due to prior surgery that prevents or hinders papillary access ______________ (e.g., gastric bypass, billroth ii, duodenal switch, roux-en-y). * gastric outlet obstruction. * situations that do not allow for upper gastrointestinal endoscopy (e.g., esophageal stricture). * patients with functional diversity, who lack the capacity to understand the nature and potential consequences of the study, except when a legal representative is available. * patients incapable of maintaining follow-up appointments (lack of adherence). * lack of informed consent.

Keywords: choledochoduodenostomy gallblader drainage lumen apposing metal stent biliary drainage biliopancreatic malignancy